Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Editor, Tachyphylaxis, defined as a diminished therapeutic response to a drug following repeated administration, has recently been documented for intravitreal bevacizumab (IVB) and ranibizumab in the treatment of exudative age-related macular degeneration (AMD) (Keane et al. 2008; Schaal et al. 2008; Forooghian et al. 2009). Its mechanism in this context is unclear, and we have speculated that the formation of circulating neutralizing antibodies (NAbs) against bevacizumab may be contributory (Forooghian et al. 2009). Systemic NAbs against humanized biologics, including ranibizumab, have previously been documented (Rosenfeld et al. 2006). In the present study, we evaluated the possibility that NAbs against bevacizumab may underlie the tachyphylactic response. We collected serum from patients who were treated with IVB for exudative AMD and had developed tachyphylaxis (n = 11), including five patients who had been described in a previous report (Forooghian et al. 2009). The comparison group included patients with exudative AMD who were naïve to IVB (n = 7) and AMD patients who were being treated with IVB but had not developed tachyphylaxis (n = 5). This prospective study was approved by the National Institutes of Health Institutional Review Board and registered (http://www.clinicaltrials.gov, NCT00605943). An enzyme-linked immunosorbent assay (ELISA) was designed to detect anti-bevacizumab antibodies in patient sera. Anti-bevacizumab antibodies were generated in immunized rabbits, and affinity-purified using standard techniques (Sigma-Genosys, The Woodlands, TX, USA). The Fab fragment of bevacizumab was prepared (Fab Preparation Kit, Pierce, Rockford, IL, USA) and used to coat 96-well high-binding polystyrene microtitre plates for an ELISA assay (1 μg/well). A standard curve was derived using purified rabbit anti-bevacizumab at varying dilutions as the primary antibody, and HRP-conjugated goat anti-rabbit IgG-Fc as the secondary antibody (1:5 000, Jackson ImmunoResearch, West Grove, PA, USA). For patient samples, undiluted sera were placed in the wells, and HRP-conjugated mouse anti-human IgG-Fc used as the secondary antibody (1:1 000 000). Color reaction was developed, and absorbance read at 450 nm. The standard curve of our ELISA assay was linear over the range of 5–40 pg/ml and was used to determine the concentration of anti-bevacizumab reactivity in patient sera. Basic demographic data, as well as mean anti-bevacizumab titres, are shown in Table 1. The anti-bevacizumab titre in patients with tachyphylaxis was higher (13.6 ± 4.7 pg/ml) than that in the control group (10.9 ± 4.9 pg/ml), a result that approached statistical significance. A one-tailed non-parametric Mann–Whitney test of the hypothesis of greater anti-bevacizumab titres in the tachyphylaxis group compared to the control group yielded a p-value of 0.052. Our results suggest that a NAb response against bevacizumab may develop following repeated IVB. However, these responses were relatively small overall (5–20pg/ml for all patients). Reported serum concentrations of NAbs against other biologic agents, such as natalizumab and infliximab, are 1000–10 000 times greater than observed here (Baert et al. 2003; Calabresi et al. 2007). These other agents are administered by intravenous infusion, achieving much higher serum concentrations than bevacizumab following intravitreal injection. The higher serum concentration of antigen in these cases would be expected to result in a higher concentration of NAbs. Interestingly, a subset of patients receiving intravitreal ranibizumab in the MARINA study also developed circulating serum antibodies to ranibizumab, with their prevalence increasing with longer treatment duration (Rosenfeld et al. 2006). The concentrations of these antibodies were however not described in the report. We determined that a minimal antibody response develops following IVB and that it may be increased in cases of tachyphylaxis. It remains uncertain that this response contributes significantly to the mechanism underlying tachyphylaxis. The small size of the response found and the borderline differences between our treatment and control groups leaves open the possibility that other mechanisms may be at play. The clinical significance of systemic anti-bevacizumab antibodies, as well as those against ranibizumab, deserves further exploration in larger studies. This work has been supported by the National Eye Institute Intramural Research Program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
FOROOGHIAN, F., CUKRAS, C., MEYERLE, C. B., CHEW, E. Y., & WONG, W. T. (2009) · Retina · doi:10.1097/iae.0b013e3181a2c1c3 · Cited by 179 · cited 7×
“Correspondence: Veronica H. Thomassen, MD Department of Ophthalmology Aalborg Sygehus Afsnit Syd Hobrovej 18-22 DK-9000 Aalborg Denmark Tel: + 45 993 223 23 Fax: + 45 993 224 56 Email: veraptr@yahoo.co.uk Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis Farzin Foro…”
BackgroundMethodSelf-citationKeane, P. A., Liakopoulos, S., Ongchin, S. C., Heussen, F. M., Msutta, S., Chang, K. T., Walsh, A. C., & Sadda, S. R. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-1689 · Cited by 145
Cited by
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
Gasperini, J. L., Fawzi, A. A., Khondkaryan, A., Lam, L., Chong, L. P., Eliott, D., Walsh, A. C., Hwang, J., & Sadda, S. R. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.204685 · Cited by 175
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
Eghøj, M. S., & Sørensen, T. L. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.203893 · Cited by 143
Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S. (2023) · BMC Ophthalmology · doi:10.1186/s12886-022-02761-9 · Cited by 9
“The factors which can influence the efficacy of antiVEGF drugs in neovascular AMD are not completely clear, and several possible explanations were reported such as increased expression of VEGF and its receptors [56], changes in signal transduction that can stimulate the expansion of CNV [57] and development of a syste…”
Background
Metadata
- Authors
- Forooghian, F., Chew, E. Y., Meyerle, C. B., Cukras, C., & Wong, W. T.
- Venue
- Acta Ophthalmologica
- Publisher
- Wiley
- Published
- 2011-02-23
- Volume
- 89
- Issue
- 2
- Pages
- e206-e207
- ISSN
- 0001-639X (ISSN-L)
- 1755-375X
- OpenAlex
- W2021225304
- Cited by
- 54
- References
- 2
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. https://app.cochat.ai/papers/10.1111/j.1755-3768.2009.01773.x
- The paper
- Forooghian, F., Chew, E. Y., Meyerle, C. B., Cukras, C., & Wong, W. T. (2011). Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmologica. https://doi.org/10.1111/j.1755-3768.2009.01773.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.